The target size of the first RMB fund of L Catterton, an investment institution under the LVMH (LVMH) group, is 2 billion yuan, and the first closing amount exceeds expectations.

The fund's investment LP (limited partner) is mainly composed of local financial investment platforms and domestic and foreign industry investors.

　　On November 1, the Beijing News Shell Finance reporter was informed that L Catterton, an investment institution under the LVMH (LVMH) group, has recently completed the first closing of its first RMB fund, and officially announced that the institution's Chinese name is "Lu." Wei Kai Teng”, and put the first phase of the LV Kai Teng RMB Fund in Chengdu High-tech Zone.

　　It is reported that the target size of LVMH's first RMB fund is 2 billion yuan, and the first closing amount exceeds expectations.

The fund's investment LP (limited partner) is mainly composed of local financial investment platforms and domestic and foreign industry investors.

　　Li Jing, director of Lovells Kaiteng, said, "Lovels Kaiteng is optimistic about the development of China's consumer industry for a long time, and we look forward to helping investee companies and partners to jointly complete the global grafting of industrial resources and the implementation of upstream and downstream commercial resources. Actively establish international ecological cooperation on a global scale."

Focusing on the Chinese market, LVMH has invested in Yuanqi Forest and HEYTEA

　　According to public information, LVMH was formed by the merger of the two funds in 2016.

They are Catterton, an American consumer private equity fund covering North America and Latin America, and L Capital, which covers private equity and real estate businesses in Europe and Asia.

At present, about 60% of the shares of LVMH are jointly held by the partners of L Capital and Catterton, and the remaining 40% belong to the Bernard Arnault family, chairman of the LVMH group.

　　After the merger, LVMH became the world's largest consumer private equity fund.

Today, LVMH has 9 investment platforms around the world, offices in 17 cities, more than 190 teams, and more than 250 cumulative investments.

Currently, LVMH's global headquarters is in the United States, while its Asian headquarters is in Singapore, with offices in Hong Kong, Beijing and Shanghai.

　　Backed by LVMH, LVMH has its own fashion "genes".

The Beijing News Shell Finance reporter found that the investment list of the agency includes the Korean trendy glasses brand Gentle Monster, the Danish fashion brand GANNI and the German shoe brand Birkenstock.

In China, luxury e-commerce company Secoo, GXG parent company Mulsanne Group, and outlet operator Sasseur have all received investment from LV Kaiteng.

　　In addition to the fashion field, LVMH has also invested in a number of consumer brands, such as Butternut Box, a British custom pet fresh food brand.

In the Chinese market, the agency has invested in local beverage brand Yuanqi Forest and tea brand Heytea in March and July 2021 respectively.

In 2022, it announced to invest in Shanghai Yiyun Pet Products Co., Ltd.

　　It is reported that the first phase of the LVMH-Kaiton RMB Fund will focus on early-stage consumer investment, including eight major segments of consumption, including overseas travel, beauty and personal care, food and beverage, pets, healthcare, consumer technology, new retail, and clothing and fashion. field.

"Giants" have successively added to the Chinese market and established investment companies only two days later

　　As Li Jing said, this time LVMH has set up a special RMB fund to show its emphasis on and confidence in the Chinese market, but this institution is not the only foreign institution that has set up a special investment fund in China in recent years.

Earlier this year, L'Oreal, the world's largest cosmetics group, and Shiseido, a beauty giant that has been deeply involved in the Chinese market for more than 40 years, also set up investment companies in the Chinese market.

　　On May 8, L'Oreal Group officially announced the establishment of Shanghai Meicifang Investment Co., Ltd. in China.

According to public information, the company's registered capital is 100 million yuan, and L'Oreal Co., Ltd. indirectly holds 100% of the equity. It mainly invests in technological innovation companies with high growth potential in marketing, digital and R&D, supply chain, packaging, etc.

　　Only two days later, Xiamen Ziyue Equity Investment Partnership (Limited Partnership) was announced. The company was jointly established by Shiseido (China) Investment Co., Ltd., Shiseido Shiyue (Shanghai) Management Consulting Co., Ltd. and Ningbo Boyu Jinghua Investment Management Co., Ltd. It holds shares with a registered capital of RMB 501 million. Its business scope includes equity investment, investment management, asset management and other activities with private funds.

Among them, Shiseido China, Shiseido Shiyue and Boyu Jinghua contributed 98%, 1.8% and 0.2% respectively.

　　According to Shiseido China’s previous announcement, Ziyue Fund will focus on emerging brands in the fields of beauty and health, as well as investment opportunities in upstream and downstream related technology service companies.

At the launch of Ziyue Fund, Shiseido China CEO Kentaro Fujiwara once said: "With the establishment of Ziyue Fund, Shiseido will be committed to promoting the high-quality development of China's beauty and health industries, stimulating domestic demand, and promoting consumption upgrades; Externally, with the advantage of Shiseido China's second global headquarters, we will promote Chinese emerging companies to enter a larger international stage."

　　According to the company's information, four months after its establishment, Shanghai Meicifang Investment Co., Ltd. made a minority investment in the local high-end perfume brand "Wenxian DOCUMENTS".

At present, Wenxian DOCUMENTS has been deployed in cities such as Beijing and Shanghai, and its stores have been set up in core business areas such as Beijing SKP-S and Shanghai Huaihai Middle Road.

The latest investment project of Ziyue Fund is Jiangsu Chuangjian Medical Technology Co., Ltd., which specializes in recombinant collagen biomaterials.

According to the announcement, the company has received nearly 200 million yuan in financing, and Huafang Capital, CDH Baifu, and Huali Pharmaceutical have also invested.